高雄市生物科技發展協會|http://www.khba.org.tw
會員登入
記住帳號 自動登入
會員名錄
各式辦法
下載專區
留言板
您目前的位置:首頁 / 活動與新訊
Novartis, Pfizer join forces on potentially lucrative fatty liver disease
活動日期:2018.10.31
2018.10.31  

Novartis, Pfizer join forces on potentially lucrative fatty liver disease
https://finance.yahoo.com/news/novartis-pfizer-join-forces-potentially-062357333.html

By John Miller and Michael Erman
ZURICH/NEW YORK (Reuters) - Novartis AG (NOVN.S) and Pfizer Inc (PFE.N) are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.
The Swiss and U.S. drugmakers announced on Monday that they will collaborate to develop combination therapies involving medicines they have been working on separately to treat nonalcoholic steatohepatitis, or NASH.
Though hardly a household name, the progressive fatty liver disease with no approved treatments is poised to become the leading cause of liver transplants by 2020. [https://reut.rs/2HojtnT]
NASH, which is closely associated with obesity and diabetes, is emerging as a major global health concern, especially among populations with increasingly fatty diets. Unchecked, it can lead to advanced cirrhosis and liver failure.
Drugmakers like Pfizer, Novartis, Gilead Sciences Inc (GILD.O) and Allergan PLC (AGN.N) see the potential $20 billion to $35 billion market, according to some estimates, as a source of future growth. Several small companies that have been focused on NASH treatments are well ahead of Pfizer and Novartis in their efforts, including Intercept Pharmaceuticals (ICPT.O) and France's Genfit (GNFT.PA).
While studies have shown increased exercise and altering dietary patterns can be a first-line of defense against the disease, Eric Hughes, who heads Novartis's hepatology development programme, has seen first hand the need for pharmaceutical options.
"As a physician, I told everyone about exercise, lifestyle changes and diet," Hughes said. "And I was lucky if I got 5 percent that even listened to me.
"This is an epidemic of 38 million people in the U.S., and to treat all those people who are advanced in their disease requires therapy," Hughes added.
The companies will test Novartis's tropifexor in various combinations with three experimental Pfizer medicines, with the idea of attacking different aspects of NASH, said Morris Birnbaum, Pfizer Internal Medicine's chief scientific officer.
"The way this disease develops is, first you get fat in the liver, and then for reasons which nobody understands, the fat provokes an inflammatory response ... and then lastly, you get scarring and fibrosis," Birnbaum said. The combination therapy would target all three stages of the disease, he said.
Pfizer's drugs are aimed at steatosis, or fat accumulation in the liver. Novartis's molecule fights inflammation and fibrotic scarring.
The collaboration is not exclusive. Novartis's 2017 partnership with Allergan testing tropifexor with an Allergan drug will continue, Hughes said.
It is too early to predict when NASH patients might receive combination Pfizer-Novartis treatments, Hughes said.
But the deal shows there is still an appetite for tackling chronic conditions that affect millions of people at a time when many drugmakers, including Pfizer and Novartis, have increasingly directed resources to treatments for rare diseases that can command extremely high prices.
(Reporting by John Miller and Michael Erman; editing by Bill Berkrot)

共有310筆資料 頁數: 第3頁(共16頁)
編號 標題 新增日期
1 You Are When You Eat 2023.12.06
2 六旬健康長者 尿道感染大腸桿菌 菌血入侵心臟 竟爆發類重度心.. 2023.12.06
3 Statins may reduce breast cancer mortality rates 2023.11.29
4 默克藥廠在台擴大投資 成立製藥頂級實驗室培訓高端人才 2023.11.29
5 Study links lifestyle choices and gender to severity of fa.. 2023.11.28
6 Base editing, a new form of gene therapy, sharply lowers b.. 2023.11.24
7 AI for drug discovery is booming, but who owns the patents? 2023.11.22
8 Unlocking the Secrets of Bacterial Transcription 2023.11.15
9 美生醫公司編輯基因降低膽固醇 預計2025年啟動2期實驗 2023.11.15
10 New nanocapsule treatment boosts immune response against s.. 2023.11.01
11 Walking and Mediterranean diet may be the ticket to reduci.. 2023.10.18
12 The Vaginal Microbiome is Finally Getting Recognized 2023.10.11
13 奈米藥物治療年輕癌症患者的效果較差且可能產生終生副作用!! .. 2023.10.11
14 Epigenetic Marks May Cause Brain Tumor Formation 2023.10.03
15 Glycogen Metabolism May Play a Key Role in Pulmonary Fibro.. 2023.09.27
16 COVID boosters are back: what scientists say about whether.. 2023.09.19
17 Journey to the Center of the Ear 2023.09.13
18 A Bacterial Culprit for Rheumatoid Arthritis 2023.09.05
19 Pet Hamsters Spread SARS-CoV-2 in Hong Kong: Preprint 2022.02.08
20 What We Learned About COVID-19 in 2021 2022.01.11
上一頁  1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16  下一頁
版權所有©2006 高雄市生物科技發展協會 所有文字、資料禁止轉用
地址:高雄市中正一路120號14樓之3 TEL:(07)591-9569 / FAX:(07)591-9018 / e-mail: khba.tw@gmail.com
累積進站人數:2897479